间充质干细胞治疗克罗恩病肛瘘研究进展

Research progress of mesenchymal stem cell in treating anal fistula in Crohn's disease

克罗恩病(Crohn's disease,CD)是一种累及全消化道的跳跃性全层炎症性肠病,肛瘘是CD常见的临床表现之一,临床发病率可达28%~43%。CD肛瘘的治疗需要结合患者的实际情况选择个体化的治疗方案,包括合适的药物种类和手术方法,目前并没有高成功率的金标准治疗方案,临床复发率较高。间充质干细胞(mesenchymal stem cell,MSC)是一种多能干细胞,具有自我更新和分化为多种类型细胞的能力,被广泛应用于再生医学领域,MSC疗法对于CD患者是一种富有前景的新选择。与传统治疗手段相比,MSC在诱导和维持瘘管闭合方面表现出更高的效率,具有很强的免疫调节作用和微创性,特别是对于瘘管复杂、常规治疗不耐受的患者。本文结合国内外最新研究报道,就MSC治疗CD肛瘘的研究进展进行综述。

Crohn's disease(CD)is a leaping full-layer inflammatory bowel disease involving the whole digestive tract.Anal fistula is one of the common clinical manifestations CD,with a clinical incidence of 28%-43%.The treatment of CD anal fistula needs to be combined with the actual situation of the patient to select an individualized treatment plan,including appropriate drug types and surgical methods.Currently,there is no gold standard treatment plan with a high success rate,and the clinical recurrence rate is high.Mesenchymal stem cells(MSC)are pluripotent stem cells that have the ability to self-renew and differentiate into multiple cell types and are widely used in the field of regenerative medicine.MSC therapy is a promising new treatment option for patients with CD.Compared with traditional treatments,MSC showed higher efficiency in inducing and maintaining fistula closure,and had a strong immunomodulatory effect and was minimally invasive.Especially for patients with complex fistulas that are intolerant to conventional treatment.Based on the latest research reports at home and abroad,this article reviews the research progress of MSC in treating anal fistula in CD.